S&P 500   3,770.91 (+0.06%)
DOW   31,038.55 (+0.37%)
QQQ   304.53 (+0.14%)
AAPL   119.41 (-0.60%)
MSFT   228.72 (+0.88%)
FB   260.31 (+1.04%)
GOOGL   2,063.52 (+1.45%)
TSLA   595.27 (-4.21%)
AMZN   2,962.71 (-0.50%)
NVDA   488.13 (-1.35%)
BABA   233.88 (+1.47%)
CGC   30.35 (-2.13%)
GE   13.72 (+1.11%)
MU   85.70 (+1.62%)
NIO   37.12 (-5.50%)
AMD   77.23 (-0.67%)
T   29.55 (+2.18%)
F   12.08 (+1.26%)
ACB   9.79 (-0.31%)
DIS   187.51 (-0.28%)
BA   223.88 (-0.37%)
NFLX   508.36 (-0.57%)
BAC   37.22 (+1.97%)
S&P 500   3,770.91 (+0.06%)
DOW   31,038.55 (+0.37%)
QQQ   304.53 (+0.14%)
AAPL   119.41 (-0.60%)
MSFT   228.72 (+0.88%)
FB   260.31 (+1.04%)
GOOGL   2,063.52 (+1.45%)
TSLA   595.27 (-4.21%)
AMZN   2,962.71 (-0.50%)
NVDA   488.13 (-1.35%)
BABA   233.88 (+1.47%)
CGC   30.35 (-2.13%)
GE   13.72 (+1.11%)
MU   85.70 (+1.62%)
NIO   37.12 (-5.50%)
AMD   77.23 (-0.67%)
T   29.55 (+2.18%)
F   12.08 (+1.26%)
ACB   9.79 (-0.31%)
DIS   187.51 (-0.28%)
BA   223.88 (-0.37%)
NFLX   508.36 (-0.57%)
BAC   37.22 (+1.97%)
S&P 500   3,770.91 (+0.06%)
DOW   31,038.55 (+0.37%)
QQQ   304.53 (+0.14%)
AAPL   119.41 (-0.60%)
MSFT   228.72 (+0.88%)
FB   260.31 (+1.04%)
GOOGL   2,063.52 (+1.45%)
TSLA   595.27 (-4.21%)
AMZN   2,962.71 (-0.50%)
NVDA   488.13 (-1.35%)
BABA   233.88 (+1.47%)
CGC   30.35 (-2.13%)
GE   13.72 (+1.11%)
MU   85.70 (+1.62%)
NIO   37.12 (-5.50%)
AMD   77.23 (-0.67%)
T   29.55 (+2.18%)
F   12.08 (+1.26%)
ACB   9.79 (-0.31%)
DIS   187.51 (-0.28%)
BA   223.88 (-0.37%)
NFLX   508.36 (-0.57%)
BAC   37.22 (+1.97%)
S&P 500   3,770.91 (+0.06%)
DOW   31,038.55 (+0.37%)
QQQ   304.53 (+0.14%)
AAPL   119.41 (-0.60%)
MSFT   228.72 (+0.88%)
FB   260.31 (+1.04%)
GOOGL   2,063.52 (+1.45%)
TSLA   595.27 (-4.21%)
AMZN   2,962.71 (-0.50%)
NVDA   488.13 (-1.35%)
BABA   233.88 (+1.47%)
CGC   30.35 (-2.13%)
GE   13.72 (+1.11%)
MU   85.70 (+1.62%)
NIO   37.12 (-5.50%)
AMD   77.23 (-0.67%)
T   29.55 (+2.18%)
F   12.08 (+1.26%)
ACB   9.79 (-0.31%)
DIS   187.51 (-0.28%)
BA   223.88 (-0.37%)
NFLX   508.36 (-0.57%)
BAC   37.22 (+1.97%)
Log in
NASDAQ:HROW

Harrow Health Stock Forecast, Price & News

$7.38
-0.18 (-2.38 %)
(As of 03/5/2021 10:07 AM ET)
Add
Compare
Today's Range
$7.38
Now: $7.38
$7.56
50-Day Range
$7.67
MA: $8.74
$11.03
52-Week Range
$3.33
Now: $7.38
$11.10
Volume1,285 shs
Average Volume264,907 shs
Market Capitalization$190.01 million
P/E RatioN/A
Dividend YieldN/A
Beta1.08
Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its products portfolio includes topical eye drop drug candidates, including SURF-100 and SURF-200; SURF-300, an oral capsule for treating patients suffering from ocular surface diseases, and DED signs and symptoms; Klarity drops to protect and rehabilitate the ocular surface pathology for patients with DED; MELT-100, a drug that is administered sublingually for conscious sedation during cataract surgery; MAY-66 that is used for the treatment of symptoms associated with Peyronie's disease; MAY-44, a non-estrogen topical analgesic gel; and other drug candidates for rare diseases. In addition, the company engages in the development of MAY-88, an oral anhydrous extend release suspension of pentosan polysulfate sodium for interstitial cystitis. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
Harrow Health logo

Headlines

Is HROW A Good Stock To Buy Now?
December 15, 2020 |  finance.yahoo.com
Harrow Health: Eye Care On The Rise
December 7, 2020 |  seekingalpha.com
Harrow Health EPS of $0.32
November 9, 2020 |  seekingalpha.com
Harrow Health, Inc. to Host Earnings Call
November 9, 2020 |  finance.yahoo.com
Earnings Outlook for Harrow Health
November 6, 2020 |  benzinga.com
Harrow Health (HROW) Enters Oversold Territory
October 27, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HROW
CUSIPN/A
CIKN/A
Phone615-733-4730
Employees133
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$51.17 million
Book Value$1.09 per share

Profitability

Net Income$170,000.00

Miscellaneous

Market Cap$190.01 million
Next Earnings Date3/8/2021 (Confirmed)
OptionableOptionable

MarketRank

Overall MarketRank

1.75 out of 5 stars

Medical Sector

191st out of 1,969 stocks

Pharmaceutical Preparations Industry

87th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
$7.38
-0.18 (-2.38 %)
(As of 03/5/2021 10:07 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HROW News and Ratings via Email

Sign-up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Harrow Health (NASDAQ:HROW) Frequently Asked Questions

Is Harrow Health a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Harrow Health stock.
View analyst ratings for Harrow Health
or view top-rated stocks.

What stocks does MarketBeat like better than Harrow Health?

Wall Street analysts have given Harrow Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Harrow Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Harrow Health's next earnings date?

Harrow Health is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Harrow Health
.

How can I listen to Harrow Health's earnings call?

Harrow Health will be holding an earnings conference call on Monday, March 8th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Harrow Health's earnings last quarter?

Harrow Health, Inc. (NASDAQ:HROW) posted its quarterly earnings results on Monday, November, 9th. The company reported $0.32 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.43. The business had revenue of $14.40 million for the quarter, compared to analysts' expectations of $8.68 million. Harrow Health had a negative trailing twelve-month return on equity of 3.52% and a negative net margin of 3.94%.
View Harrow Health's earnings history
.

How has Harrow Health's stock price been impacted by Coronavirus?

Harrow Health's stock was trading at $4.76 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HROW stock has increased by 58.8% and is now trading at $7.56.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for HROW?

1 brokerages have issued twelve-month price objectives for Harrow Health's stock. Their forecasts range from $14.00 to $14.00. On average, they anticipate Harrow Health's stock price to reach $14.00 in the next year. This suggests a possible upside of 85.2% from the stock's current price.
View analysts' price targets for Harrow Health
or view top-rated stocks among Wall Street analysts.

Who are Harrow Health's key executives?

Harrow Health's management team includes the following people:
  • Mr. Mark L. Baum, CEO & Director (Age 48, Pay $802.78k)
  • Mr. Andrew R. Boll C.F.A., C.M.A., CFA, CMA, CFO & Corp. Sec. (Age 39, Pay $539.78k)
  • Mr. John P. Saharek, Pres of ImprimisRx (Age 61, Pay $463.33k)
  • Mr. David Moufarrège, VP of Technology
  • Dr. Dennis E Saadeh Pharm.D., Chief of Formulation Strategy
  • Dr. Larry M. Dillaha, Chief Medical Officer
  • Mr. Andrew Livingston, Chief Innovation Officer

Who are some of Harrow Health's key competitors?

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).

What is Harrow Health's stock symbol?

Harrow Health trades on the NASDAQ under the ticker symbol "HROW."

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Opaleye Management Inc. (11.91%), BlackRock Inc. (5.95%), Renaissance Technologies LLC (5.80%), Uniplan Investment Counsel Inc. (1.96%), Northern Trust Corp (1.26%) and Ikarian Capital LLC (1.20%). Company insiders that own Harrow Health stock include Opaleye Management Inc and Robert J Kammer.
View institutional ownership trends for Harrow Health
.

Which major investors are selling Harrow Health stock?

HROW stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Northern Trust Corp, Corrado Advisors LLC, and Baystate Wealth Management LLC.
View insider buying and selling activity for Harrow Health
or view top insider-selling stocks.

Which major investors are buying Harrow Health stock?

HROW stock was purchased by a variety of institutional investors in the last quarter, including Uniplan Investment Counsel Inc., Renaissance Technologies LLC, Opaleye Management Inc., BlackRock Inc., Assenagon Asset Management S.A., JPMorgan Chase & Co., Wells Fargo & Company MN, and Diametric Capital LP.
View insider buying and selling activity for Harrow Health
or or view top insider-buying stocks.

How do I buy shares of Harrow Health?

Shares of HROW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harrow Health's stock price today?

One share of HROW stock can currently be purchased for approximately $7.56.

How much money does Harrow Health make?

Harrow Health has a market capitalization of $194.64 million and generates $51.17 million in revenue each year. The company earns $170,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

How many employees does Harrow Health have?

Harrow Health employs 133 workers across the globe.

What is Harrow Health's official website?

The official website for Harrow Health is www.harrowinc.com.

Where are Harrow Health's headquarters?

Harrow Health is headquartered at 102 Woodmont Blvd. Suite 610, Nashville TN, 37205.

How can I contact Harrow Health?

Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The company can be reached via phone at 615-733-4730 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.